Cargando…

Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer

BACKGROUND: With the improvement of therapeutic strategies from cytotoxic chemotherapy to immunotherapy, the possibility of achieving timely intervention for lung cancer has dramatically increased. This study aimed to systematically evaluate the reporting quality of randomized controlled trials (RCT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Jun, Zhang, Yundi, Dong, Yiting, Duan, Jianchun, Bai, Hua, Wang, Jie, Xu, Jiachen, Wang, Zhijie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520800/ https://www.ncbi.nlm.nih.gov/pubmed/34432361 http://dx.doi.org/10.1111/1759-7714.14114

Ejemplares similares

Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization
por: Sun, Yiting, et al.
Publicado: (2022)

Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma
por: He, Xiran, et al.
Publicado: (2020)

Current status and progress in immunotherapy for malignant pleural mesothelioma
por: Sun, Boyang, et al.
Publicado: (2022)

Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy
por: Zhao, Jie, et al.
Publicado: (2023)

Establishment of prognostic nomograms for predicting the progression free survival of EGFR‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs
por: Du, Xinyang, et al.
Publicado: (2022)

High‐fidelity of non‐small cell lung cancer xenograft models derived from bronchoscopy‐guided biopsies
por: Fu, Shuai, et al.
Publicado: (2015)

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
por: Wu, Xinyu, et al.
Publicado: (2023)

Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non–small cell lung cancers
por: Han, Jiefei, et al.
Publicado: (2021)

Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer
por: Zhao, Zhe, et al.
Publicado: (2020)

Correlation among genetic variations of c-MET in Chinese patients with non-small cell lung cancer
por: Duan, Jianchun, et al.
Publicado: (2017)

Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non–Small Cell Lung Cancer: A Phase 1 Trial
por: Wang, Zhijie, et al.
Publicado: (2020)

MMR gene patterns evaluation provides novel insights for personalized immunotherapy compared to neoadjuvant chemotherapy in lung adenocarcinama
por: Cai, Liangliang, et al.
Publicado: (2023)

The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis
por: Zhao, Zhe, et al.
Publicado: (2020)

PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non‐small cell lung cancer
por: Dong, Yiting, et al.
Publicado: (2022)

Prevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma
por: Li, Zhenxiang, et al.
Publicado: (2015)

Pegylated recombinant human granulocyte colony‐stimulating factor regulates the immune status of patients with small cell lung cancer
por: Sun, Jing, et al.
Publicado: (2020)

MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review
por: Dong, Yiting, et al.
Publicado: (2022)

Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung
por: Duan, Jianchun, et al.
Publicado: (2015)

Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC
por: Sun, Yiting, et al.
Publicado: (2021)

EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma
por: Bai, Hua, et al.
Publicado: (2020)

Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer
por: Yang, Xue, et al.
Publicado: (2016)

Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
por: Dong, Yiting, et al.
Publicado: (2022)

Hypoxia‐inducible factor‐1α and nuclear factor‐κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non‐small‐cell lung cancer cells
por: Guo, Rong, et al.
Publicado: (2019)

Efficacy and safety of weekly intravenous nanoparticle albumin‐bound paclitaxel for non‐small cell lung cancer patients who have failed at least two prior systemic treatments
por: Duan, Jianchun, et al.
Publicado: (2017)

Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer
por: Bai, Hua, et al.
Publicado: (2013)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Abnormal activation of NF‐κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid‐derived suppressor cells to shape the immunosuppressive tumor immune microenvironment
por: Wang, Chao, et al.
Publicado: (2023)

Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors
por: Zhang, Pei, et al.
Publicado: (2022)

Combined Immunotherapy with Chemotherapy versus Bevacizumab with Chemotherapy in First-Line Treatment of Driver-Gene-Negative Non-Squamous Non-Small Cell Lung Cancer: An Updated Systematic Review and Network Meta-Analysis
por: Chai, Yue, et al.
Publicado: (2022)

Recommendations of individualized medical treatment and common adverse events management for lung cancer patients during the outbreak of COVID‐19 epidemic
por: Zhao, Zhe, et al.
Publicado: (2020)

Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC
por: Huang, Yiyi, et al.
Publicado: (2023)

Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
por: Wang, Shuhang, et al.
Publicado: (2015)

Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non‐small cell lung cancer
por: Zhang, Pei, et al.
Publicado: (2020)

IMPACT: A web server for exploring immunotherapeutic predictive and cancer prognostic biomarkers
por: Liu, Yutao, et al.
Publicado: (2023)

ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer
por: Cai, Liangliang, et al.
Publicado: (2020)

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer
por: Wan, Rui, et al.
Publicado: (2023)

Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non–small cell lung cancer
por: Chang, Geyun, et al.
Publicado: (2022)

First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China
por: Qi, Fei, et al.
Publicado: (2019)

DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer
por: Zhu, Jian, et al.
Publicado: (2012)

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
por: Wang, Zhijie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2678sm2cu4irh7sor9s618hibq